{
    "clinical_study": {
        "@rank": "134581", 
        "arm_group": [
            {
                "arm_group_label": "MatriStem Pelvic Floor Matrix", 
                "arm_group_type": "Experimental", 
                "description": "surgical mesh device"
            }, 
            {
                "arm_group_label": "Native Tissue Repair", 
                "arm_group_type": "Active Comparator", 
                "description": "suture repair"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to assess the safety and effectiveness of MatriStem\n      Pelvic Floor Matrix as compared to native tissue repair for the treatment of pelvic organ\n      prolapse.  Patients are evaluated throughout a 3 year follow-up period."
        }, 
        "brief_title": "ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study", 
        "condition": "Pelvic Organ Prolapse", 
        "condition_browse": {
            "mesh_term": [
                "Prolapse", 
                "Pelvic Organ Prolapse"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject's leading edge of POP is at or beyond the hymen.  At or beyond the hymen is\n             defined as POP-Q scores of Ba \u2265 0 or Bp \u2265 0 or C \u2265 0 (for prolapse of the apical\n             compartment alone) or C \u2265 -\u00bd total vaginal length (for a multi-compartment prolapse\n             that includes the apical compartment).\n\n          -  Subject is seeking surgical intervention for symptomatic POP, which is defined as\n             experiencing symptoms of vaginal bulging or pelvic heaviness.  Vaginal bulge or\n             pelvic heaviness will be considered present if a subject responds \"yes\" (\u22651) to\n             PFDI-20, question 3.\n\n          -  Subject or subject's legally authorized representative is willing to provide written\n             informed consent.\n\n          -  Subject is willing and able to comply with the follow-up regimen.\n\n        Exclusion Criteria:\n\n          -  Subject has a known hypersensitivity to porcine-based materials (relevant to subjects\n             in MatriStem Pelvic Floor Matrix Group only).\n\n          -  Subject is pregnant or plans to become pregnant during the study.\n\n          -  Subject has an active or chronic systemic infection including any gynecologic\n             infection, urinary tract infection (UTI), or tissue necrosis.\n\n          -  Subject has a known neurologic or medical condition affecting bladder function (e.g.\n             multiple sclerosis, spinal cord injury, or stroke with residual neurologic deficit).\n\n          -  Subject has chronic systemic pain syndrome (e.g. fibromyalgia, painful bladder\n             syndrome).\n\n          -  Subject has a systemic connective tissue disease (e.g., scleroderma, systemic lupus\n             erythematous (SLE), Marfans syndrome, Ehlers Danhlos, collagenosis, polymyositis or\n             polymyalgia rheumatica).\n\n          -  Subject has uncontrolled diabetes mellitus (DM).\n\n          -  Subject has a history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or\n             cervical).\n\n          -  Subject has had prior or is currently undergoing radiation, laser therapy, or\n             chemotherapy in the pelvic area.\n\n          -  Subject has taken systemic steroids (within the last month), immunosuppressive or\n             immunomodulatory treatment (within the last 3 months).\n\n          -  Subject is seeking obliterative vaginal surgery as treatment for POP (colpoclesis).\n\n          -  Subject is not able to conform to the modified dorsal lithotomy position.\n\n          -  Subject is currently participating in or plans to participate in another device or\n             drug study during this study.\n\n          -  Subject is to planning to undergo concurrent surgical treatment of prolapse using\n             mesh other than the MatriStem Pelvic Floor Matrix."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "162", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02021279", 
            "org_study_id": "ACL2012-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "MatriStem Pelvic Floor Matrix", 
                "intervention_name": "MatriStem Pelvic Floor Matrix", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Native Tissue Repair", 
                "intervention_name": "native tissue repair", 
                "intervention_type": "Procedure", 
                "other_name": "suture repair"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pelvic organ prolapse", 
            "MatriStem", 
            "pelvic floor matrix", 
            "ACell", 
            "native tissue repair"
        ], 
        "lastchanged_date": "December 20, 2013", 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Use of Transvaginal Resorbable Biologic Mesh as Compared to Traditional Non-Mesh Surgical Repair for Treating Pelvic Floor Disorders", 
        "overall_contact": {
            "email": "michellekofron@acell.com", 
            "last_name": "Michelle D Kofron, PhD", 
            "phone": "410-973-8502"
        }, 
        "overall_contact_backup": {
            "email": "cindymattingly@acell.com", 
            "last_name": "Cindy Mattingly", 
            "phone": "410-953-9539"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The composite outcome of surgical success evaluates anatomic outcome, patient reported outcome, and no retreatment pelvic organ prolapse.", 
            "measure": "The safety and effectiveness of surgical success/failure.", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02021279"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "A composite outcome of surgical success based on an alternate definition of anatomic success, patient reported outcome, and no retreatment for pelvic organ prolapse.", 
            "measure": "The surgical success/failure based on an alternate definition of success.", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "source": "ACell Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ACell Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}